Blumenschein, George R.;
Glisson, Bonnie S.;
Lu, Charles;
Sabichi, Anita Lyn;
Ginsberg, Lawrence E.;
Bartos, Claudia I.;
Feng, Lei;
Tran, Hai T.;
El-Naggar, Adel K.;
Lippman, Scott Michael;
Kies, Merrill S.
Final results of a phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN)
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Final results of a phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN)
Contributor:
Blumenschein, George R.;
Glisson, Bonnie S.;
Lu, Charles;
Sabichi, Anita Lyn;
Ginsberg, Lawrence E.;
Bartos, Claudia I.;
Feng, Lei;
Tran, Hai T.;
El-Naggar, Adel K.;
Lippman, Scott Michael;
Kies, Merrill S.
Published:
American Society of Clinical Oncology (ASCO), 2012
Published in:
Journal of Clinical Oncology, 30 (2012) 15_suppl, Seite 5592-5592
Description:
5592 Background: Cytotoxic chemotherapy (CT) is the current standard treatment for metastatic/recurrent SCCHN. The prognosis for these patients (PTS) is poor with a median progression free survival (PFS) of 4 months with CT. Survival in PTS with SCCHN may correlate inversely with the number of angiogenic growth factors secreted. Sorafenib is a potent inhibitor of c-Raf, b-Raf, VEGFR-1/2/3 and PDGFR-β. To investigate the hypothesis that a multi-targeted TKI added to chemotherapy would improve outcomes in patients with metastatic/recurrent SCCHN, we performed a phase II trial of paclitaxel and carboplatin and sorafenib (PCS). Methods: PTS were required to have ECOG PS 0-1, measurable disease, controlled blood pressure, and may have received one regimen of induction, concomitant or adjuvant CT, but not CT for recurrent/metastatic disease. Sites of primary disease excluded nasopharynx and paranasal sinus. Treatment consisted P 200mg/m2 and C AUC 6 intravenously on day 1 followed by S 400 mg orally bid (days 2-19) in every 3-week cycles. Primary endpoint was PFS, targeting median PFS of 6 months (M). Secondary endpoints include overall survival (OS), response rate (RR), exploratory biomarkers, and toxicity. Results: Forty-eight PTS with SCCHN were enrolled with 44 PTS evaluable for PFS and response using RECIST. Median age: 56 years (22-79 years), 89% male, median ECOG PS 1. Median follow-up was 24.1 M. RR was 55% (n=24), disease control rate was 84% (n=37), median PFS was 8.51 M (95% CI: 5.98 ~ 13 months), and median OS was 22.6 M (95% CI: 13.1 - NA months). Grade ³3 treatment related toxicities included hand-foot syndrome (n=10), neutropenia (n=5), pain (n=6), elevated lipase (n=4), elevated amylase (n=3), anemia (n=3), fatigue (n=2), hypertension (n=2), neuropathy (n=2), febrile neutropenia (n=2), and thrombocytopenia (n=2). Conclusions: The combination of PCS was well tolerated and had encouraging activity in recurrent/metastatic SCCHN. Blood-based and tissue biomarkers are being analyzed. Final outcomes, toxicity, and correlative biomarker data will be reported.